These phase III clinical studies, supported by Top10 pharma laboratories, will be using the tablet-based data capture solution developed by Kayentis. They will be conducted in 700 research centers in 50 countries and will affect 5,000 patients.
Signing up these clinical studies has confirmed the presence of Kayentis as a global player in the capture and management of patient data (eClinical Outcome Assessment). For Guillaume Juge, « the success achieved among these leading laboratories has confirmed our ambition to offer the pharmaceutical industry high-level, dependable solutions for performant economic conditions ».
As experts in electronic data capture for patients in clinical trials, Kayentis has been involved in clinical development since 2003, helping sponsors and CROs to bring simplicity to the collection of clinical trials data for both patients and sites. Since 2009, Kayentis has specialized in eCOA solutions, developing a full range of services and extending its solutions portfolio. The company has continued to enhance its services and now offers a wide range of solutions that are easily used together and adaptable for all clinical study needs.
